Comparable stake leader
RHUMBLINE ADVISERS
SEC ownership of ASLAN Pharmaceuticals Ltd
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001722926.
Disclosed value leader
RHUMBLINE ADVISERS
Comparable rows
0/1
Latest evidence
31 Mar 2026
- Parsed ownership sources
- 13F
- Largest SEC-reported holder
- RHUMBLINE ADVISERS
- Latest parsed ownership date
- 31 Mar 2026
- Issuer CIK
- 0001722926
- Issuer location
- Singapore, Singapore
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of ASLAN Pharmaceuticals Ltd (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
RHUMBLINE ADVISERS
Disclosed value leader
RHUMBLINE ADVISERS
Comparable rows
0/1
Latest evidence
31 Mar 2026
13F
Highest disclosed value: $17
1 rows are not safely comparable across share classes.
Quick read
RHUMBLINE ADVISERS has the largest disclosed position value at $17.
0 of 1 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens RHUMBLINE ADVISERS's linked filing trail.
Disclosed position value
Top 1
RHUMBLINE ADVISERS
$17
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-1 of 1 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| RHUMBLINE ADVISERS |
13F
Company
|
—
class O/S missing
|
$17
29 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 06 Jun 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Recent insider transactions for ASLAN Pharmaceuticals Ltd
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.